COMMUNIQUÉS West-GlobeNewswire

Amoéba receives its first order from Koppert and confirms its transformation into a commercial company
12/03/2026
Chassieu, March 12, 2026 (GLOBE NEWSWIRE) -- Amoéba receives its first order from Koppert and confirms its transformation into a commercial company Chassieu (France), 11 March 2026 – 6:00 pm - Amoéba (FR0011051598 - [...]
BioLongevity Labs Publishes 2026 Research Peptide Vendor Report as Global Synthesis Market Hits $1.9 Billion
12/03/2026
The report evaluates top peptide suppliers against documentation depth, analytical standards, and third-party testing practices. Akron, OHIO, March 12, 2026 (GLOBE NEWSWIRE) -- BioLongevity Labs, a U.S. GMP-certified [...]
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
12/03/2026
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
12/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Th é a Open Innovation Galimedix receives [...]
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
12/03/2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health Access the segment [...]
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
12/03/2026
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
12/03/2026
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical [...]
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated [...]
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
12/03/2026
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial [...]
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
12/03/2026
- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential [...]
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
12/03/2026
Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report [...]
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana [...]
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
12/03/2026
CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
12/03/2026
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and [...]
Marine Biologics Unveils SeaTex™ For Clean Label Nutritional Design And Performance
12/03/2026
Novel single-ingredient seaweed powder designed for high-performance stabilization dramatically simplifies product formulations with zero additives or synthetic ingredients BERKELEY, Calif., March 12, 2026 (GLOBE [...]
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
12/03/2026
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today [...]
Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia
12/03/2026
CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune [...]
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
12/03/2026
$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure [...]

Pages